IREN proposes $875 million convertible notes offering due 2031
Arcutis Biotherapeutics Inc stock reached a 52-week high, hitting 18.17 USD. This milestone reflects a significant upward trend for the company, which now commands a market capitalization of $2.15 billion. According to InvestingPro analysis, the company maintains impressive gross profit margins of 89.1% and has achieved nearly 100% revenue growth over the past year. The stock’s impressive performance is underscored by a remarkable 93.87% increase over the last 12 months. This surge indicates strong investor confidence, with analysts setting price targets ranging from $19 to $29. InvestingPro analysis suggests the stock may still have upside potential, with 10 additional exclusive insights available to subscribers. As Arcutis Biotherapeutics continues to advance its therapeutic innovations, its stock performance remains a focal point for investors and analysts alike, with detailed analysis available in the comprehensive Pro Research Report.
In other recent news, Arcutis Biotherapeutics reported its earnings for the second quarter of 2025, surpassing both earnings per share (EPS) and revenue forecasts. The company posted an EPS of -$0.13, beating the forecast of -$0.17, and reported revenue of $81.5 million, exceeding expectations by 11.26%. Additionally, Arcutis has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration to expand the use of ZORYVE cream for treating plaque psoriasis in children as young as 2 years old. If approved, ZORYVE would be the first topical PDE4 inhibitor indicated for this age group.
In related news, Palvella Therapeutics has appointed David W. Osborne, Ph.D., as Chief Innovation Officer. Dr. Osborne, a co-founder of Arcutis Biotherapeutics, brings over 25 years of experience in developing topical therapies for skin diseases. His contributions include the development of ZORYVE cream and foam. These developments highlight recent strategic and financial activities within both companies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.